Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 4 studies | 24% ± 8% | |
hepatocyte | 3 studies | 30% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney | 3 studies | 34% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 4659.16 | 89 / 89 | 94% | 33.58 | 848 / 901 |
pancreas | 92% | 492.39 | 303 / 328 | 75% | 4.45 | 134 / 178 |
liver | 90% | 680.77 | 203 / 226 | 45% | 3.00 | 181 / 406 |
breast | 97% | 967.80 | 446 / 459 | 37% | 2.07 | 414 / 1118 |
prostate | 100% | 1246.31 | 245 / 245 | 30% | 0.92 | 151 / 502 |
bladder | 100% | 1315.52 | 21 / 21 | 14% | 0.73 | 70 / 504 |
esophagus | 89% | 959.97 | 1289 / 1445 | 21% | 1.05 | 39 / 183 |
lung | 94% | 569.20 | 544 / 578 | 16% | 0.64 | 189 / 1155 |
intestine | 89% | 705.38 | 863 / 966 | 14% | 0.63 | 72 / 527 |
blood vessel | 100% | 4865.32 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 95% | 770.93 | 1148 / 1204 | 0% | 0 | 0 / 0 |
uterus | 76% | 431.86 | 129 / 170 | 18% | 1.08 | 84 / 459 |
thymus | 73% | 320.52 | 475 / 653 | 15% | 1.00 | 88 / 605 |
adrenal gland | 63% | 243.90 | 163 / 258 | 23% | 1.84 | 53 / 230 |
stomach | 58% | 399.91 | 208 / 359 | 26% | 1.34 | 74 / 286 |
skin | 68% | 344.91 | 1227 / 1809 | 7% | 0.48 | 32 / 472 |
spleen | 74% | 385.07 | 179 / 241 | 0% | 0 | 0 / 0 |
heart | 72% | 923.20 | 616 / 861 | 0% | 0 | 0 / 0 |
ovary | 31% | 190.33 | 55 / 180 | 9% | 0.50 | 39 / 430 |
muscle | 14% | 50.05 | 115 / 803 | 0% | 0 | 0 / 0 |
brain | 10% | 41.16 | 271 / 2642 | 2% | 0.07 | 12 / 705 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.15 | 2 / 45 |
eye | 0% | 0 | 0 / 0 | 3% | 0.06 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030178 | Biological process | negative regulation of Wnt signaling pathway |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_1904808 | Biological process | positive regulation of protein oxidation |
GO_0006508 | Biological process | proteolysis |
GO_0031334 | Biological process | positive regulation of protein-containing complex assembly |
GO_0031090 | Cellular component | organelle membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0017147 | Molecular function | Wnt-protein binding |
GO_0004222 | Molecular function | metalloendopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | TRABD2B |
Protein name | Metalloprotease TIKI2 (EC 3.4.-.-) (Heart, kidney and adipose-enriched transmembrane protein homolog) (TRAB domain-containing protein 2B) |
Synonyms | TIKI2 HKAT |
Description | FUNCTION: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation. . |
Accessions | ENST00000606738.3 A6NFA1 |